Navigation Links
China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health
Date:7/15/2010

BEIJING, July 15 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its HER-2 FISH probe has been chosen to be used in a research project focusing on cancer targeted therapy standardization, as well as early cancer detection and treatment, which is sponsored by the Chinese Ministry of Health. One of the subjects of this research project is to standardize the process and procedures for the use of FISH technology to detect HER-2 gene amplification in breast cancer and stomach cancer patients to guide the use of Herceptin (the "HER-2 Study"). The Company is the supplier of HER-2 FISH probe for the HER-2 Study.

Immunohistochemistry used to be the traditional diagnostic method in detecting HER-2 gene amplification in China, but it has false positive and false negative results. The HER-2 Study is the first study in China to include FISH technology as the gold standard in HER-2 gene amplification detection. The Company believes that the results of the HER-2 Study may contribute to more widespread use of its HER-2 FISH probe in the companion diagnostic test market in China for guiding treatment for breast cancer and stomach cancer. According to the Chinese Central Government's Official Web Portal, about 200,000 new cases of breast cancer and 400,000 new cases of stomach cancer are diagnosed in China each year.

"We believe that our selection as the supplier of HER-2 FISH probe in the HER-2 Study by the top ranking cancer research institute demonstrates the good quality of our HER-2 FISH probe," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.

The HER-2 Study is led by the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences with Dr. Yuankai Shi as the principal investigator.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit http://www.chinameditech.com .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including the risk that the results of the HER-2 Study will not lead to increased use of the Company's HER-2 FISH probe. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    For more information, please contact:

     Winnie Yam
     Phone: +852-2511-9808
     Email: IR@chinameditech.com


'/>"/>
SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MarketsandMarkets: Patient Monitoring Devices Markets in Brazil, Russia, India and China Worth $2,992 Million by 2015
2. Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair
3. China Medicine Announces Stock Repurchase Plan
4. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
5. New Report Patient Monitoring Emerging Markets (BRIC - Brazil, Russia, India and China) 2010 - 2014 Published by MarketsandMarkets
6. China-Biotics, Inc. Announces US$20 million Share Buyback Program
7. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
8. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
9. China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
10. Samplify Expands Global Presence; Opens China Office
11. China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Consolidated Stability Storage is Leading to CROs ... Outsourcing Market This research service on the global ... and technologies, and provides a snapshot of the key ... and forecasts are provided from 2016 to 2020. ... CAGR of 9.4% till 2020, driven by an explosion ...
(Date:1/23/2017)... -- MouthWatch LLC announced today that its flagship product, the ... intraoral camera on DentalCompare,s list of Top Dental Products ... product was the CollaPlug Absorbable Collagen Wound Dressing . ... popular because it is by far the most economical option ... it doesn,t sacrifice quality imaging." ...
(Date:1/23/2017)... , Jan. 23, 2017 7D Surgical ... clearance from the U.S. Food and Drug Administration ... Canada enabling the North American commercial launch of ... for spine surgery, the 7D Surgical System.  ... 3D optical technologies and machine vision algorithms to ...
Breaking Medicine Technology:
(Date:1/23/2017)... NY (PRWEB) , ... January 23, 2017 , ... ... today that John J. Nelson, a senior accountant at the Firm, will participate in ... Make-A-Wish® Hudson Valley. Over 200 runners will race up 1,576 steps, a vertical distance ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... Crystallization in Process Chemistry by Applying Simple PAT Tools . , ... to isolate and purify the desired product. Chemists now spend more time ...
(Date:1/23/2017)... , ... January 23, 2017 ... ... Foundation (OREF), in partnership with the American Society of Anesthesiologists® (ASA®), the ... (APSF), the American Academy of Orthopaedic Surgeons (AAOS) and the Cigna Foundation, ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the wilderness ... of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education at ... master’s degree in education in the field of curriculum and instruction. Kimberly’s passion for ...
Breaking Medicine News(10 mins):